Pharma Mar, S.A.
General ticker "PHMMF" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.6B (TTM average)
Pharma Mar, S.A. follows the US Stock Market performance with the rate: 3.1%.
Estimated limits based on current volatility of 0.1%: low 94.45$, high 94.64$
Factors to consider:
- Company pays dividends (irregularly): last record date 2026-07-09, amount 1.14$ (Y1.21%)
- Earnings for 18 months up through Q2 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [50.36$, 93.71$]
- 2025-12-31 to 2026-12-31 estimated range: [42.54$, 80.77$]
Financial Metrics affecting the PHMMF estimates:
- Positive: with PPE of 54.0 at the end of fiscal year the price was neutral
- Negative: Operating cash flow per share per price, % of 0.44 <= 2.37
- Positive: 0.56 < Operating profit margin, % of 3.70
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: 0.07 < Interest expense per share per price, % of 0.18
- Negative: 58.56 < Shareholder equity ratio, % of 59.59 <= 69.38
- Negative: negative Industry operating income (median)
- Negative: Industry earnings per price (median), % of -21.03 <= 0
- Positive: -0.14 < Investing cash flow per share per price, % of 0.08
Short-term PHMMF quotes
Long-term PHMMF plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | €196.34MM | €158.15MM | €174.85MM |
| Operating Expenses | €152.27MM | €161.98MM | €168.39MM |
| Operating Income | €44.07MM | €-3.83MM | €6.47MM |
| Non-Operating Income | €-0.28MM | €0.20MM | €5.52MM |
| Interest Expense | €2.38MM | €2.42MM | €2.47MM |
| R&D Expense | €83.45MM | €99.30MM | €103.50MM |
| Income(Loss) | €43.79MM | €-3.62MM | €11.98MM |
| Taxes | €0.00MM | €-4.76MM | €0.00MM |
| Net Income(Loss)* | €49.36MM | €1.14MM | €26.12MM |
| Stockholders Equity | €222.96MM | €193.44MM | €208.36MM |
| Inventory | €27.75MM | €39.29MM | €50.89MM |
| Assets | €393.26MM | €340.52MM | €349.64MM |
| Operating Cash Flow | €38.32MM | €-13.45MM | €6.03MM |
| Capital expenditure | €8.85MM | €15.96MM | €15.51MM |
| Investing Cash Flow | €10.88MM | €-43.05MM | €1.03MM |
| Financing Cash Flow | €-13.37MM | €-32.14MM | €-5.35MM |
| Earnings Per Share** | €2.73 | €0.06 | €1.49 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.